Sevoflurane
Sevoflurane, Sojourn, Ultane (sevoflurane) is a small molecule pharmaceutical. Sevoflurane was first approved as Ultane on 1995-06-07. It is used to treat pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sevoflurane, Sojourn, Ultane
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sevoflurane | ANDA | 2025-10-03 |
| sevoflurane bostonbio | ANDA | 2020-09-09 |
| sevoflurane, (volatile for inhalation) | ANDA | 2025-08-06 |
| sojourn | ANDA | 2025-09-19 |
| ultane | New Drug Application | 2025-02-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1155 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia recovery period | D000762 | — | — | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 1 | — | 1 |
| Vaginal diseases | D014623 | — | — | — | — | — | 1 | — | 1 |
| Calculi | D002137 | — | — | — | — | — | 1 | — | 1 |
| Ureteral obstruction | D014517 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | — | 1 | 1 | — | — | 1 |
| Cystoscopes | D020684 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sevoflurane |
| INN | sevoflurane |
| Description | Sevoflurane is an ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups. It has a role as an inhalation anaesthetic, a platelet aggregation inhibitor and a central nervous system depressant. It is an organofluorine compound and an ether. It is functionally related to a 2-methoxypropane. |
| Classification | Small molecule |
| Drug class | general inhalation anesthetics (halogenated alkane derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | FCOC(C(F)(F)F)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 28523-86-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200694 |
| ChEBI ID | 9130 |
| PubChem CID | 5206 |
| DrugBank | DB01236 |
| UNII ID | 38LVP0K73A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Sevoflurane – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 38,419 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,346 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use